Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretion
控制肝脏apoB-Lp脂质负荷和分泌的新调控机制
基本信息
- 批准号:10628991
- 负责人:
- 金额:$ 47.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AdipocytesAdipose tissueApoprotein (B)AtherosclerosisBiogenesisBiological AssayBiologyBody Weight decreasedCatabolismCellsCholesterol EstersChylomicronsCirculationCollaborationsComplementCore FacilityCytoplasmDataDegradation PathwayDiglyceridesEncapsulatedEndoplasmic ReticulumEnterocytesEventFatty LiverFatty acid glycerol estersGene ExpressionGenerationsGolgi ApparatusHepaticHepatocyteHypertriglyceridemiaIn VitroKineticsKnockout MiceLinkLipidsLipolysisLipoproteinsLiverMembraneMembrane LipidsMetabolicModelingMolecularMolecular ChaperonesMusNamesOutcomeOutputPathogenicityPathway interactionsPeripheralPlayProteinsPublicationsQuality ControlRegulationRepressionRoleSiteSmooth Endoplasmic ReticulumSourceSteatohepatitisSystemTestingTissuesTranscriptTransferaseTranslatingTriglyceridesVery low density lipoproteinVesicleWorkatherogenesisbariatric surgerydefined contributionendoplasmic reticulum stressfatty liver diseasein vivomicrosomal triglyceride transfer proteinmouse modelmulticatalytic endopeptidase complexnon-alcoholic fatty liver diseasenovelobese patientsparticlesynergismtraffickingvesicle transport
项目摘要
The global hypothesis underlying this PPG application is that crosstalk between adipose, liver, and intravascular
lipolysis regulates the biogenesis of atherogenic apoB-containing lipoproteins, most notably VLDLs. Project 2
(P2) focuses on mechanisms that control the generation of apoB/VLDL in liver cells. Prior work from the PI and
Co-I, which has resulted in 14 publications, established that a major mechanism controlling circulating
apoB/VLDL is the regulated degradation of apoB in the endoplasmic reticulum (ER). This metabolically
orchestrated event requires the ER-associated degradation (ERAD) pathway, which was named and first
elucidated by the Co-I. Under lipid-poor conditions, the ERAD of apoB begins with its selection by molecular
chaperones, which is followed by apoB ubiquitinylation and delivery to the cytoplasmic proteasome. In contrast,
when neutral lipids (primarily triacylglycerols) are in excess, apoB is co-translationally lipidated by MTP, and the
nascent apoB/VLDL particles are expanded by lipids sourced from ER resident lipid droplets (LDs), and the re-
modelled apoB/VLDL particle is packaged into COPII vesicles for delivery to the Golgi and then into circulation.
In contrast, the events that regulate the number and composition of lipids assembled with apoB—as well as the
packaging of engorged, lipid-rich apoB/VLDL particles into COPII vesicles—are poorly characterized. To these
ends, results generated by the PI and his colleagues indicate that two factors, ER-resident proteins KLHL12 and
FIT2, play a significant role in controlling lipid assembly onto apoB and the encapsulation of apoB/VLDL into
COPII vesicles in vitro and in vivo. These recently acquired data support several new hypotheses: First, that
KLHL12 resides at apoB exit sites on the ER that include COPII components, and second that the inefficient
integration of apoB into COPII vesicles selects the protein for the recently characterized ER-phagy pathway,
which was also elucidated by the Co-I. A characterization of a new liver-specific KLHL12 knockout mouse will
be used to define the role of KLHL12 in non-alcoholic fatty liver disease and steatohepatitis. In turn, other recently
acquired preliminary data indicate that FIT2 deficiency increases ER membrane lipid content along with the
generation of lipid-depleted apoB/VLDLs. Based on the function of FIT2 in forming cytosolic LDs, these data
underscore another novel hypothesis, that FIT2 delivers LDs into the ER, where they are then integrated into
pre-apoB/VLDL particles in either an MTP-dependent or independent manner. A new liver-specific FIT2 knockout
mouse will concomitantly allow for a study of the links between FIT2 and fatty liver disease and steatohepatitis,
and also atherosclerosis (because of FIT2 regulation of apoB/VLDL lipid content and composition). Broadly, the
Specific Aims of this application are: (1) To define the mechanisms underlying KLHL12-dependent regulation of
lipid-rich apoB/VLDL encapsulation into hepatic ER-derived, Golgi-directed transport vesicles, and (2) To define
the impact of FIT2 on lipid loading of apoB/VLDL particles and their atherogenicity, both of which require critical
collaborations with P1, P3, and Core facilities.
PPG 应用的总体假设是脂肪、肝脏和血管内的细胞之间的串扰
脂肪分解调节含 apoB 的致动脉粥样硬化脂蛋白的生物发生,尤其是 VLDL。项目2
(P2) 重点关注肝细胞中控制 apoB/VLDL 生成的机制。 PI 之前的工作和
Co-I 已发表 14 份出版物,建立了控制流通的主要机制
apoB/VLDL 是 apoB 在内质网 (ER) 中受调节的降解。这在代谢上
精心策划的事件需要 ER 相关降解 (ERAD) 途径,该途径最初被命名
由 Co-I 阐明。在脂质匮乏的条件下,apoB 的 ERAD 从分子选择开始
分子伴侣,随后进行 apoB 泛素化并递送至细胞质蛋白酶体。相比之下,
当中性脂质(主要是三酰甘油)过量时,apoB 会被 MTP 共翻译脂质化,并且
新生的 apoB/VLDL 颗粒通过来自 ER 驻留脂滴 (LD) 的脂质进行扩展,并且重新
模型化的 apoB/VLDL 颗粒被包装到 COPII 囊泡中,输送到高尔基体,然后进入循环。
相比之下,调节与 apoB 组装的脂质数量和组成的事件以及
将充盈的富含脂质的 apoB/VLDL 颗粒包装到 COPII 囊泡中的过程尚不清楚。对这些
最后,PI 和他的同事产生的结果表明,两个因素,ER 驻留蛋白 KLHL12 和
FIT2 在控制脂质组装到 apoB 以及将 apoB/VLDL 封装到
COPII 囊泡在体外和体内。这些最近获得的数据支持几个新假设:首先,
KLHL12 位于 ER 上的 apoB 出口位点,其中包括 COPII 成分,其次是低效的
将 apoB 整合到 COPII 囊泡中,为最近表征的 ER 吞噬途径选择了蛋白质,
Co-I 也对此进行了阐述。新型肝脏特异性 KLHL12 敲除小鼠的表征将
用于定义 KLHL12 在非酒精性脂肪肝和脂肪性肝炎中的作用。反过来,其他最近
获得的初步数据表明,FIT2 缺乏会增加内质网膜脂含量,同时也会增加内质网膜脂含量。
产生脂质耗尽的 apoB/VLDL。基于 FIT2 在形成胞质 LD 中的功能,这些数据
强调了另一个新颖的假设,即 FIT2 将 LD 传递到 ER 中,然后将它们整合到
前apoB/VLDL颗粒以MTP依赖或独立的方式。一种新的肝脏特异性 FIT2 敲除方法
小鼠将同时允许研究 FIT2 与脂肪肝疾病和脂肪性肝炎之间的联系,
还有动脉粥样硬化(因为 FIT2 调节 apoB/VLDL 脂质含量和组成)。从广义上讲,
本申请的具体目标是:(1) 定义 KLHL12 依赖性调节的潜在机制
富含脂质的 apoB/VLDL 封装到肝 ER 衍生的、高尔基定向的转运囊泡中,以及 (2) 定义
FIT2 对 apoB/VLDL 颗粒的脂质负荷及其致动脉粥样硬化性的影响,这两者都需要关键
与 P1、P3 和核心设施的合作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edward A Fisher其他文献
Technology Insight: targeting of biological molecules for evaluation of high-risk atherosclerotic plaques with magnetic resonance imaging
技术洞察:利用磁共振成像靶向生物分子以评估高危动脉粥样硬化斑块
- DOI:
10.1038/ncpcardio0013 - 发表时间:
2004-11-01 - 期刊:
- 影响因子:44.200
- 作者:
Michael J Lipinski;Valentin Fuster;Edward A Fisher;Zahi A Fayad - 通讯作者:
Zahi A Fayad
Rapid regression of atherosclerosis: insights from the clinical and experimental literature
动脉粥样硬化的快速消退:来自临床和实验文献的见解
- DOI:
10.1038/ncpcardio1086 - 发表时间:
2008-02-01 - 期刊:
- 影响因子:44.200
- 作者:
Kevin Jon Williams;Jonathan E Feig;Edward A Fisher - 通讯作者:
Edward A Fisher
Edward A Fisher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edward A Fisher', 18)}}的其他基金
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
- 批准号:
10424901 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Administrative, Biostatistics, Data Management, and Bioinformatics Core
行政、生物统计学、数据管理和生物信息学核心
- 批准号:
10616527 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
- 批准号:
9209582 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
- 批准号:
10424904 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
- 批准号:
10616525 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Macrophage Dysfunction in Atherosclerosis and Cardiometabolic Diseases
动脉粥样硬化和心脏代谢疾病中的巨噬细胞功能障碍
- 批准号:
10424900 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Resolving Macrophage Inflammation in Atherosclerotic Plaques and Other Sites in Insulin Resistance
解决动脉粥样硬化斑块和胰岛素抵抗其他部位的巨噬细胞炎症
- 批准号:
10616536 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Macrophage Dysfunction in Obesity, Diabetes and Atherosclerosis
肥胖、糖尿病和动脉粥样硬化中的巨噬细胞功能障碍
- 批准号:
9925242 - 财政年份:2017
- 资助金额:
$ 47.3万 - 项目类别:
Beta-catenin signaling in endothelial cells during cerebral malaria
脑型疟疾期间内皮细胞中的β-连环蛋白信号传导
- 批准号:
9144854 - 财政年份:2015
- 资助金额:
$ 47.3万 - 项目类别:
相似海外基金
Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
- 批准号:
MR/Y013891/1 - 财政年份:2024
- 资助金额:
$ 47.3万 - 项目类别:
Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
- 批准号:
BB/Y006542/1 - 财政年份:2024
- 资助金额:
$ 47.3万 - 项目类别:
Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
- 批准号:
23H03323 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
- 批准号:
23K08293 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
- 批准号:
479570 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
- 批准号:
488898 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
- 批准号:
23K19922 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
- 批准号:
10605981 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
- 批准号:
10813753 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
- 批准号:
10604611 - 财政年份:2023
- 资助金额:
$ 47.3万 - 项目类别:














{{item.name}}会员




